Tagged Articles

Xarelto 120 articles

J&J blames disappointing 1Q sales on Invokana, Xarelto performance

Invokana

Johnson & Johnson’s recently reported first quarter earnings report dropped more than 3 percent on the day the news was announced, a rarity for a fairly stable stock, according to NASDAQ analysts. The consumer health care and pharmaceutical giant is blaming the weak first-quarter earnings on price discounting in certain sales channels, as well as competition for the underperformance of its pharmaceuticals. Specifically, sales of J&J’s type 2 diabetes drugs Invokana and Invokamet fell almost 16.8 percent in the U.S. due to lower prices. The company’s blood thinner Xarelto, manufacturered in partnership with Bayer, saw a slight increase in prescription share, ... Read More

Lawsuits allege Xarelto is unreasonably dangerous in design

xarelto

Johnson & Johnson’s Janssen Pharmaceuticals and Bayer face a potential $2.5 billion in potential liability over uncontrolled bleeding allegedly caused by their blockbuster blood thinner Xarelto. More than 16,000 cases are pending in a multidistrict litigation (MDL) in Louisiana, with the bellwether scheduled to start next week. U.S. District Judge Eldon E. Fallon shot down a preemption argument in a defense summary, which allowed state-law design-defect claims by those suing drug companies to move forward. Janssen and Bayer had argued that the defective design claims are preempted by federal law, and that it would be virtually impossible for them to ... Read More

GI bleeds more common with Xarelto than Eliquis or Pradaxa

xarelto

In a study pitting three of the newer anticoagulants for stroke prevention in patients with the common heart rhythm abnormality atrial fibrillation, gastrointestinal (GI) bleeds appeared to occur less often in the newest of the three. The blood thinners – Pradaxa, Xarelto and Eliquis – were the first novel anticoagulants (NOACs) to receive Food and Drug Administration (FDA) approval, in 2010, 2011 and 2012, respectively. Pradaxa, manufactured by Boehringer Ingelheim, contains the drug ingredient dabigatran. Xarelto, made by Johnson & Johnson’s Janssen Pharmaceuticals and Bayer, contains rivaroxaban. Eliquis, produced jointly by Bristol-Myers Squibb and Pfizer, contains the active ingredient apixaban. ... Read More

Real-world data reveals bleeding risk with Xarelto

xarelto

Real-world data analysis pitting the newer blood thinners Xarelto, Pradaxa and Eliquis against the long-used warfarin show the newer meds were in some cases more effective at preventing strokes in patients with atrial fibrillation than warfarin. But the bleeding side effects may outweigh the benefit for some of the meds. Xarelto, Eliquis and Pradaxa were first introduced to the market in 2010 and are now used to prevent strokes in patients with the common heart rhythm abnormality atrial fibrillation. They are also used to treat other blood clot-related health issues. The newer drugs were designed to be more convenient alternatives ... Read More

Johnson and Johnson suffers record courtroom losses in 2016

talc justice

“Johnson & Johnson had a year for the record books — it lost six of 2016’s seven largest jury verdicts in the U.S. over product defect claims. This year may be no better,” wrote Bloomberg in an article titled “Why Johnson & Johnson Would Like to Forget 2016: QuickTake Q&A.” The news site discusses the harsh realities of J&J’s courtroom losses last year. Johnson and Johnson’s losses far exceeded $20 million. Bloomberg reports that most companies only suffer two or three verdicts exceeding $20 million related to product defects in a year. Losses are more than merely a verdict, as the ... Read More

Consumer Reports: 10 dietary supplements to avoid if you’re taking heart drugs

supplement - Wikipedia

People taking medication for high blood pressure, high cholesterol or other cardiovascular problems should avoid at least 10 dietary supplements, according to a new study published in the Journal of the American College of Cardiology. Researchers say the supplements can reduce the effectiveness of heart drugs or cause dangerous side effects. “Natural does not mean safe,” said Graziano Onder, MD, PhD, with the Universita Cattolica del Sacro Cuore in Rome. Many dietary supplements tout that they are “all natural” when in fact they contain synthetic ingredients or even hidden drug ingredients. Onder and his team set out to look at the ... Read More

J&J faces more potential million-dollar product liability judgments in 2017

johnsonandjohnson

The world’s largest health care company, Johnson & Johnson, was slapped with six of the seven largest product liability verdicts in 2016, and 2017 is shaping up to be just as woeful with the company facing potential verdicts totaling into the hundreds of millions of dollars. J&J faces at least 17 state and federal trials this year involving serious injuries and deaths allegedly caused by the company’s pharmaceuticals, medical devices, and consumer products. Last year the company was hit with a $1 billion judgment over faulty hip implants, a $72 million verdict involving ovarian cancer claims with Johnson’s baby powder, and ... Read More

Xarelto makers test drug on patients with CAD, PAD

xarelto

A study investigating the effectiveness of the blood thinner Xarelto in patients with coronary artery disease (CAD) or peripheral arty disease (PAD) was halted prematurely after an interim analysis showed the medication helped prevent heart attacks, strokes and cardiovascular death. But the study has yet to reveal the rate of bleeding events, a known side effect of Xarelto. CAD and PAD are conditions in which there is a narrowing and blocking of the arteries in various critical regions of the body. CAD affects the heart’s arteries whereas PAD usually affects the arteries in the legs, but can also be used ... Read More

Newer blood thinners linked to new adverse events

xarelto

Analyses of so-called real life data comparing a newer class of blood thinners with the long-used warfarin has revealed new adverse events not previously associated with the anticoagulants. Direct oral anticoagulants, such as Pradaxa, Xarelto and Eliquis, hit the market beginning in 2010 and are quickly vying for market share under warfarin. They are used to prevent strokes in patients with atrial fibrillation, to treat and prevent deep vein thrombosis and pulmonary embolism, and to prevent blood clots in people who have recently undergone hip or knee replacement surgery. The drugs are gaining popularity over warfarin because they are more ... Read More

There remains an unmet need for novel anticoagulant reversal agent

xarelto

With the increasing popularity of new novel anticoagulants over the long-used warfarin for the prevention of strokes in atrial fibrillation and other blood clot-related conditions, there remains an unmet need for an antidote to reverse the blood thinning effects of the drugs in the event of a bleeding emergency. The new line of blood thinners were introduced in 2010 and include the direct thrombin inhibitor Pradaxa, and the oral factor Xa inhibitors Xarelto, Eliquis and Savaysa. All anticoagulants increase the risk of major uncontrolled bleeding and life-threatening bleeding events, including gastrointestinal bleeds, rectal bleeds, and brain bleeds. There are currently ... Read More